CD19-Targeted CAR T Cell Therapy for Concomitant Diffuse Large B Cell Lymphoma and Myeloma

While DLBCL and myeloma comprise a large fraction of annual hematologic malignancies, the co-occurrence of these malignancies is particularly rare. The FDA has approved three CD19-targeted CAR T cell therapies for B-cell lymphoma (Kymriah, Yescarta, and Brenyazi) and more recently a single CAR T cel...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2021-11, Vol.138 (Supplement 1), p.4811-4811
Hauptverfasser:	D'Ovidio, Tyler J, Ciccolini, Kathryn, Kalac, Matko, Osman, Keren, Steinberg, Amir
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!